Reports Q4 revenue $266.1M, consensus $248.64M. CEO Mary Puma commented, "2022 was another outstanding year for Axcelis. As a result of strong execution by the Axcelis team and robust demand for the Purion product family, we delivered record quarterly and annual revenues, and we surpassed our $850M revenue model. For the full year 2023 Axcelis revenues are expected to exceed $1B and we are introducing a new long-term implant only model with revenue of $1.3B that we believe is achievable within the next 2 to 3 years." CFO Kevin Brewer said, "We are extremely pleased with our 2022 results, and very excited about our projected growth. As a result of the success of Purion and tight control of our cost structure, Axcelis’ profitability has improved significantly and we expect further gains in 2023 and beyond."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACLS:
- Axcelis Announces Financial Results for Fourth Quarter and Full Year 2022
- Axcelis announces follow-on shipments of the Purion H current implanter
- Axcelis reports multiple Purion Power Series implanter orders
- Axcelis price target raised to $115 from $95 at B. Riley
- Axcelis price target raised to $113 from $94 at Craig-Hallum
